OXIDATIVE STRESS CORRECTION WITH METABOLIC PREPARATIONS, NEW POSSIBILITIES OF ANTIOXIDANT PROTECTION IN PRIMARY GLAUCOMA

There were studied antioxidant action of water-soluble form of quercetin – corvitin and melatonin in rabbits with glaucoma model. It was shown intravenous injections of corvitin essentially decreased oxidative stress in animals with advanced stage of experimental glaucoma. Prophylactic-protective apply of melatonin on the basis of model induction in significant degree protected oxidative stress development.

Key words: quercetin; melatonin; glaucoma; oxidative stress

INTRODUCTION

Today it is known that mechanisms of free radical damage and oxidative stress play an important role in the pathogenesis of primary glaucoma, contributing primarily formation of glaucomatous optic neuropathy [15, 22]. The formation of active atoms or molecules with unpaired electron in an outer orbit, so-called free radicals, in the body takes place continuously. However, under physiological conditions, the amount and rate of their formation is compensated by the speed of the elimination with antioxidants. Imbalance in the amount and activity of pro-oxidants and antioxidants leads to oxidative stress. This mechanism, in turn, can lead to damage of cell macromolecules, membrane degradation and change functions that contribute to making cell death.

According to some authors [17, 12] the formation of oxidative stress caused by unstable ocular blood flow is one of the main risk factors for glaucomatous optic neuropathy. As it states in repeated mild reperfusion, as a consequence of unstable blood flow, a large amount of free radicals is formed. Reperfusion injury occurs when the blood supply returns to the tissue after a period of ischemia. This mechanism is probably the most traumatic for the eye tissues, especially the nervous structures of the eye. Oxidative stress, which occurs in the conditions of reperfusion, the most severely damages the mitochondria. These organelles are present in large numbers in the optic nerve, as a structure with high energy consumption. The damage of the mitochondria disrupts the production of energy, leading to malnutrition and neural cell degeneration [11].

Besides effects on the nervous tissue, glaucoma oxidative stress may cause degeneration of the trabecular meshwork and be thus trigger mechanism for raising intraocular pressure (IOP), changing the paths of outflow of intraocular fluid [21, 10]. The idea of a pathogenic role of oxidative stress in raising IOP is supported by a number of researchers. Thus, it was shown that patients with primary open angle glaucoma (POAG) had have a decrease in the total antioxidant activity of intraocular fluid, reduced glutathione levels [10, 13]. The use of antioxidants in an attempt to treat glaucoma was started by S.C. Evans. He used of large doses of vitamins A and C [9, 16]. It was assumed that vitamin A supports dehydrated status of collagen in the eye drainage system, and hydration of collagen structures in the outflow tract leading to increased IOP. High doses of vitamin C reduce IOP by osmotic effect, although this method is hardly practical use for the control of glaucoma in the present conditions.

In this regard, it is important that the treatment strategy of glaucoma gradually changes. It is receding into the past approach to doctoring it as a disease, not related to other organs and the organism as a whole. In search of strategies to treat this pathology as the suffering of “a sick organ in a sick body” the use antioxidants with systemic effects is reasonable. The use of the natural origin medication with minimal side effects, in our view, is the most appropriate. In this direction, carried out a study on the effectiveness of glaucoma treatment with the antioxidant effect drugs such as lipoic acid [6], pyridine derivative (an analogue of vitamin B6) emoksipin [1], carotenoids of ginkgo biloba extract and lutein [4, 20].

In the study of the possibility of increasing the effectiveness of antioxidant effects in primary glaucoma our focus attracted such biologically active substances with a very powerful antioxidant potential as quercetin and melatonin. The antioxidant properties of bioflavonoids quercetin are determined by its chemical structure, which
allows it to counteract the damaging effects of reactive oxygen species and free radicals, i.e., are natural scavengers. In addition to the ability to be “free radical scavengers”, quercetin prevents lipid peroxidation and chelating metal ions [14]. It’s proved for Quercetin neuroprotective possibility in neurodegenerative diseases (Alzheimer’s, Parkinson’s, epilepsy, stroke) and cardioprotective effects in cardiovascular diseases. The mechanism of this protection is linked with the antioxidant activity of quercetin [3, 7, 23].

Melatonin is a synthesis product of a pineal gland (epiphysis) and other organs, including the retina, has been known mainly as a regulator of circadian rhythms in the body. Recently it became known antioxidant properties of melatonin. It has been identified as a direct scavenger of free radicals [19] and indirect antioxidant – regulator of antioxidant enzymes activity [18]. Melatonin is highly active endogenous antioxidant and its lipophilic properties allows it to diffuse into the various cell compartments and provide a protective effect against cytotoxic free radicals both in the cytoplasm and in the nucleus. Clinical trials have shown that the antioxidant properties of melatonin may be effective in the treatment of acute medical conditions (sepsis, asphyxia) or chronic diseases (metabolic and neurodegenerative diseases, cancers, inflammation) [8].

The purpose of our study was to investigate the antioxidant activity of melatonin and quercetin preparations on glaucoma model in rabbits.

MATERIALS AND METHODS

As a quercetin-containing preparation we used domestic product Corvitin for injection, which is a freeze-dried substance of quercetin with polyvinylpyrrolidone as a modifier of solubility. We also used domestic product Vita-melatonin. It is a synthetic analog of neuropeptide melatonin produced by the pineal gland.

The investigations were carried out on rabbits, which glaucoma was caused by systemic administration of adrenalin according to the developed scheme [5]. The study includes the following groups: control group – healthy animals; advanced glaucoma model (GM), a glaucoma model, treated with Corvitin (GMC); a reproducible of glaucoma model (GM). In GMC group rabbits with developed experimental glaucoma obtained Corvitin as 10 daily intravenous infusions (2 % solution of the preparation in isotonic saline) at a dose of 10 mg/0.5 ml.

In GMC group rabbits obtained Melatonin in the form of an aqueous suspension per os at a dose of 0.3 mg for 4 months; the entire period of the modeling, as well as before and 2 weeks after the induction of the model.

Biochemical studies were conducted in animal blood plasma. Malonic dialdehyde (MDA) was determined by reaction with thiobarbituric acid, the total antioxidant activity of blood plasma (TAOA) – using a model system with linolenic acid. The statistical data processing was carried out using t-test.

### RESULTS AND DISCUSSION

Our study of pro- and antioxidant status of animals with the induced glaucoma have confirmed our previous results [2] and found a high level of oxidative stress in animals of group GM. It has been manifested by an increase in the content of secondary product of lipid per-oxidation MDA by 103 % (compared to control), and a decrease in antioxidant status, reflected in a reduction of 40 % TAOA in blood plasma (Table).

Introduction of Corvitin intravenous injections to GMC group rabbits with the ocular and metabolic functions disorders has largely hindered severity of oxidative stress in them. In this group MDA levels compared to the control was increased by 22 % and TAOA reduced by 16.1 %. Comparing the severity of oxidative stress in the GMC and GM groups it has been revealed that under the influence of Corvitin high MDA levels have been decreased by 39.2 % and TAOA has been increased by 40.3 % in blood of rabbits with developed glaucoma.

Under long-term administration of melatonin in GMM group has been largely prevented the development of oxidative stress in the simulation of glaucoma. Thus, the content of MDA in a month after the 4-months administration of melatonin has been increased by 13.7 % and TAOA – reduced by 13.2 % compared with the control. When comparing these results with the untreated GM group, MDA levels has been lower by 44.9 % and TAOA – above by 33.5 % under the action of melatonin.

Thus, the study of the activity of quercetin-containing Corvitin and melatonin in the experiment showed that both of these compounds with known antioxidant properties proved to be effective in the inducing of glaucoma in rabbits by means of chronic stressing adrenaline. Both of these substances expressed direct antioxidant property as scavengers of free radicals, which are indirectly judged by the decrease the level of secondary lipid per-oxidation product in the blood of experimental animals. Furthermore, as quercetin and melatonin in our experi-
CONCLUSIONS
1. Introduction of 10 intravenous injections of quercetin-containing Corvitin to rabbits with advanced stage of glaucoma model significantly reduced the severity of oxidative stress in them.
2. Preventive and treat administration of the stress protective hormone melatonin during 4 months in rabbits with reproducible adenrealine glaucoma model has largely prevented the formation of oxidative stress in them.
3. The experimental data, which showed significant antioxidant effects of Corvitin and melatonin in experimental glaucoma, can serve as a basis for recommending the use of these preparations in the clinic of primary glaucoma.

REFERENCES
1. Kramorenko Yu. S. Emokuspin in the treatment of primary glaucoma / Yu. S. Kramorenko, T. A. Dobrnya, Z. A. Ivanbaeva, E. A. Egorov // Vestnik oftalmol. – 1992. – № 1. – С. 14-15.
2. Michievska I. N. Oxidant and potential applications in human disease oxidative stress / I. N. Michievska // Patol. – 2008. – Т. 5, № 3. – С. 125-126.
3. Mozhetova L. K. Lutein-complex in the treatment of glaucomatous optic nerve damage (Corvinit) in the treatment of the late stage of the cardiovascular syndrome with atherosclerosis / L. K. Mozhetova, I. B. Alekseeva, A. V. Iashina // Clin. oftalmol. – 2005. – Т. 6, № 2. – С. 67-69.
4. Pat. Ukrainy № 61478 A 61K. Spособ моделирования адреналин-индукованной глauкомы у кроликов / I. M. Michievska. – Opubl.: 25.07.11. – Biol. № 14.
5. Filina A. A. Antioxidant antioxidant therapy of primary glaucoma / A. A. Filina // Vestnik oftalmol. – 1994. – Т. 110, № 1. – С. 33-35.
6. Ansari M. A. Protective effect of quercetin in primary neurons against Abeta (1-42): relevance to Alzheimer’s disease / [M. A. Ansari, H. M. Abdul, G. Joshi et al.] // J. Nutr. Biochem. – 2009. – Vol. 20, № 4. – P. 269-275.
7. Bonnefont-Rousselot D. Melatonin: action as antioxidant and potential applications in human disease and aging / D. Bonnefont-Rousselot, F. Collin // Toxicol. – 2010. – Vol. 278. – P. 55-67.
8. Evans S. C. Ophthalmic nutrition and prevention of eye disorder and blindness / Nutrition Metabolism. – 1977. – Vol. 21. – P. 268-272.
9. Ferreira S. M. Oxidative stress markers in aqueous humor of glaucoma patients / [S. M. Ferreira, S. F. Lerner, R. Brunzini et al.] // Am. J. Ophthamol. – 2004. – Vol. 137. – P. 62-69.
10. Flammer J. Glaucomatous optic neuropathy: a reperfusion injury // Klin. Monatsbl. Augenheilkd. – 2000. – Vol. 218. – P. 290-291.
11. Flammer J. What is the present pathogenetic concept of glaucomatous optic neuropathy? / J. Flammer, M. Mozaffarieh // Surv. Ophthalmol. – 2007. – Vol. 52. – P. 162-173.
12. Gherghel D. Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma / [D. Gherghel, H. R. Griffths, E. J. Hilton et al.] // Invest. Ophthamol. Vis. Sci. – 2005. – Vol. 46. – P. 877-883.
13. Harwood M. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties / [M. Harwood, B. Daniellwska-Nikel, J. F. Borzelleca et al.] // Food Chem. Toxicol. – 2007. – Vol. 45. – P. 2179-2205.
14. Izzotti A. The role of oxidative stress in glaucoma / A. Izzotti, A. Bagmis, S. C. Sacca // Mutat. Res. – 2006. – Vol. 612. – P. 105-114.
15. Krishna S. M. Vitamin A and primary glaucoma / S. M. Krishna, P. K. Shukla // J. Glaucoma. – 1982. – Vol. 4. – P. 226-227.
16. Mozaffarieh M. Oxygen and blood flow: players in the pathogenesis of glaucoma / M. Mozaffarieh, M. Grieshaber, J. Flammer // Mol. Vis. – 2008. – Vol. 14. – P. 224-233.
17. Reiter R. J. Melatonin reduces oxidant damage and promotes mitochondrial respiration: implications for aging / R. J. Reiter, D. X. Tan, L. C. Manchester, M. R. El-Sawi // Ann. NY Acad. Sci. – 2002. – Vol. 959. – P. 238-250.
18. Reiter R. J. Melatonin: Lowering the High Price of Free radicals / R. J. Reiter // News Phisiol. Sci. – 2000. – Vol. 15. – P. 246-250.
19. Ritch R. Potential role gingo biloba extract in the treatment of glaucoma / R. Ritch // Med. Hypotheses. – 2000. – Vol. 54, № 2. – P. 221-235.
20. Sacca S. C. Glaucomatous outflow pathway and oxidative stress / S. C. Sacca, A. Izzotti, P. Rossi, C. Traverso // Exp. Eye Res. – 2007. – Vol. 84. – P. 389-399.
21. Tezel G. Oxidative stress in glaucoma neurodegeneration: mechanism and consequences // Prog. Retin Eye Res. – 2006. – Vol. 25, № 5. – P. 490-513.
22. Vauzour D. The neuroprotective potential of flavonoids: a multiplicity of effects / [D. Vauzour, K. Vafeiadou, A. Rodriguez-Mateos et al.] // Genes Nutr. – 2008. – № 3. – P. 115-126.
І. М. Михейцева, В. М. Єльський
КОРЕКЦІЯ ОКСИДАТИВНОГО СТРЕСУ МЕТАБОЛІЧНИМИ ЗАСОБАМИ, НОВІ МОЖЛИВОСТІ АНТИОКСИДАНТНОГО ЗАХИСТУ ПРИ ПЕРВИННІЙ ГЛАУКОМІ

Вивчено на моделі глаукоми у кролів антиоксидантну дію водорозчинної форми кверцетину-корвітину та препарату мелатоніну. Показано, що курс внутрішньовенних введення корвітину суттєво знизив оксидативний стрес у тварин з розвитою стадією експериментальної глаукоми. Профілактично-протекторне введення мелатоніну на тлі індуkcії моделі значною мірою завадило розвитку оксидативного стресу.

Ключові слова: кверцетин; мелатонін; глаукома; оксидативний стрес

УДК 617.7-07.681-092

И. Н. Михейцева, В. Н. Ельский
КОРРЕКЦИЯ ОКСИДАТИВНОГО СТРЕССА МЕТАБОЛІЧЕСКИМИ СРЕДСТВАМИ, НОВЫЕ ВОЗМОЖНОСТИ АНТИОКСИДАНТНОЙ ЗАЩИТЫ ПРИ ПЕРВИЧНОЙ ГЛАУКОМЕ

На модели глаукомы у кроликов изучено антиоксидантное действие водорастворимой формы кверцетина – корвітину и препарата мелатонин. Показано, что курс внутривенных инъекций корвітину существенно снизил оксидативный стресс у животных с развитой стадией экспериментальной глаукомы. Профилактически-протекторное длительное введение мелатонина на фоне индуkcии модели в значительной степени предотвратило развитие оксидативного стресса.

Ключевые слова: кверцетин; мелатонин; глаукома; оксидативный стресс

Адреса для листування:
65061, м. Одеса, Французький бульвар, 49/51.
ДУ «Інститут очних хвороб і тканиної терапії ім. В. П. Філатова НАМН України»

Надійшла до редакції 11.04.2016 р.